Fadogia Agrestis

The verdict

Is Fadogia Agrestis worth taking?

No, and this is the clearest case in the guide. Not because the evidence is mixed, but because of how little there is and what the rest of it says.

The entire testosterone claim is one experiment. Published in 2005, in rats, five days long, with five animals per group at each time point. Testosterone was reported as fold-changes read off a graph rather than as values anyone can check. It has never been replicated — not by an independent group, not in another species, not once in twenty-one years. Every page you will read about this compound traces to that single paper.

The same laboratory then ran it for 28 days and published three papers on what happened. At 50 and 100 mg/kg the authors reported irreversible derangement of testicular histology, with destruction of spermatogenic cells. At all three doses, including the lowest, they found the enzyme pattern of membrane damage in liver and kidney, with serum malondialdehyde nearly tripled. Their own words about the lowest dose are that the recovery seen there "suggests that it does not exhibit permanent toxicity at this dose" — which tells you what they thought about the other two.

And the dose comparison everyone makes is backwards. The standard claim is that the toxic rat doses correspond to something like 1,500 mg a day in a human, far above the 600 mg typically taken. Scale it properly by body surface area and 600 mg a day lands at roughly the lower of the two doses where the damage was irreversible. The scaling carries real uncertainty, set out below, but the reassuring version has no source at all.

There is no human trial of this compound, of any design, anywhere. Not a randomized trial, not an open-label study, not a case series. Examine states it. WebMD states it. Several of the sites selling the dosing protocol state it, and then give the protocol anyway.

The mechanism everyone repeats was never measured. "It works by raising luteinizing hormone" appears on vendor pages, podcast summaries and retailer blogs. Luteinizing hormone has never been measured in any Fadogia agrestis experiment. It is inference presented as finding.

Overhyped is the grade, and it is the only defensible one.

What it does

What Fadogia Agrestis does in the body

Marketed for testosterone boosting and libido enhancement. Zero published human clinical trials support these applications. All testosterone evidence comes from rat studies showing dose-dependent LH stimulation and increased testicular weight, the same studies that also showed dose-dependent testicular, liver, and kidney toxicity at higher doses.

The evidence

What the research actually shows

The 2005 study, in full, because it is the whole case. Male albino rats, 270 to 300 grams, four groups of fifteen with five monitored per group at each of days 1, 3 and 5. An aqueous extract of the plant's stem, at 18, 50 and 100 mg/kg, once daily for five days. At day five the paper reports serum testosterone roughly two, three and six times control across the three doses, and increased mounting and intromission frequency at the top dose.

Three things about that. The testosterone data appear only as a figure, so the two-, three- and sixfold numbers repeated everywhere are the authors' own prose summary of a graph, not values with error bars. Five animals per group at a single time point producing a sixfold hormone swing is the profile of a result that does not replicate. And the paper never states whether its milligrams per kilogram refer to dried extract or to starting plant material, and reports no extraction yield — which means every human dose comparison ever published, including the one on this page, inherits that ambiguity.

The 18 mg/kg dose was not chosen pharmacologically. It is the dose used in local folk medicine, from the authors' own ethnobotanical survey.

What else exists. A 2023 paper from the same senior author looked at erectile function markers in rats given an antidepressant, using the same three doses — and did not measure testosterone. Two papers characterize the plant's chemistry. One Nigerian study gave an acute lethal dose above 5,000 mg/kg in root extract, which is the number most often cited to argue the compound is safe. It is a single-dose lethality test with one animal per group in the high-dose phase, and it says nothing about what 28 days of dosing does to an organ. That distinction is the entire safety story here.

No human data of any kind. A 2025 narrative review in a men's health journal found one Fadogia study worth including — the 2023 rat paper — and concluded only that the plant should be tested in clinical trials. No trial appears in the published literature, and four independent sources state that none exists.

A specific error worth naming. A major retailer's editorial page cites an 11 to 15 percent increase in testicular weight in rodents as "a marker of enhanced reproductive tissue development." Those numbers are the testes-to-body-weight ratios from the 2008 paper — the one whose authors described the changes as indications of adverse effects on testicular function. It is the toxicity data with the sign flipped.

What came next

What the same laboratory found when it ran the study for 28 days

The 2005 testosterone paper is cited everywhere. The three papers that followed it, from the same group using the same extract at the same three doses, are cited almost nowhere.

Testicular histology, 28 days plus a 10-day recovery period, 40 rats. The abstract states it plainly: toxicity was mild and reversible at 18 mg/kg, "but there was irreversible derangement on male testicular histology at 50 and 100 mg/kg body weight dose regimen." The sections showed dose-dependent lesions running from mild distortion of the seminiferous tubules to complete destruction of spermatogenic cells. The authors' conclusion warns of permanent lesions affecting male reproductive function.

Testicular biochemistry, 28 days. At every dose, testicular protein fell by about 40 percent, alkaline phosphatase fell by two-thirds or more, and glutamate dehydrogenase fell progressively to about a quarter of control at the top dose, while cholesterol more than doubled. The authors described these as indications of adverse effects on testicular function that may affect the functional capacity of the testes.

Liver and kidney, 28 days. Tissue enzyme activity fell while the same enzymes rose in serum — the signature of enzymes leaking out of damaged cells. Serum malondialdehyde, a marker of lipid peroxidation, rose roughly threefold. This happened at all three doses, including the lowest. And the animals looked fine: no deaths, no clinical signs, no change in organ weights relative to body weight. Which is the point worth carrying away — whatever this does, it does it without announcing itself.

One more thing about the histology paper. It contains the single most important safety finding about this compound, and it was published in a journal almost nobody will ever find. That is part of why the claim survives.

The arithmetic

The dose comparison that everyone gets backwards

The reassuring line, repeated across the sites that do mention the toxicity, is that the damaging rat doses correspond to roughly 1,500 mg a day or more in a human — comfortably above the 600 mg people actually take. I could not find a source for that figure anywhere.

Done properly, using the FDA's own published method for converting animal doses to human equivalents by body surface area, the numbers run the other way:

Rat dose	Human equivalent, 60 kg	What happened in rats at 28 days
18 mg/kg	about 175 mg/day	Mild, reversible testicular distortion. Liver and kidney enzyme leakage
50 mg/kg	about 487 mg/day	Irreversible testicular derangement
100 mg/kg	about 973 mg/day	Irreversible. Complete destruction of spermatogenic cells

The commonly taken dose is 600 mg a day. Some products are sold at 1,200.

Two reasons this calculation is uncertain, and I am not going to bury them. First, the rat papers never state whether their milligrams per kilogram mean extract or starting plant material, and give no extraction yield — so if their dose was raw plant powder and a commercial capsule is a genuine concentrate, the comparison could move substantially in either direction. Second, body-surface-area scaling is a method for choosing a safe starting dose in a first human trial, not a validated way to translate a toxicity threshold for a crude plant extract of unknown composition.

So the honest statement is not that 600 mg is toxic. Nobody knows. It is that the universally repeated claim that 600 mg sits comfortably below the threshold has no source behind it, and the most defensible calculation available puts it inside the range where the damage was described as permanent. That is a meaningful difference when the organ in question is the one you are taking the supplement for.

Reading the label

Five of seventeen products contained none of it

Set the biology aside for a moment. There is a separate question about whether a capsule contains the plant at all, and it has been tested twice.

A 2019 analysis in Planta Medica from the University of Mississippi's natural products center measured eleven constituents across seventeen retail dietary supplements claiming to contain Fadogia agrestis. Twelve of them contained the phenolic compounds, at 0.3 to 2.7 mg per daily dose — itself a ninefold spread between products sold at the same capsule weight. In five of the seventeen, the compounds were not detected.

A companion study fingerprinted seven commercial products against authenticated plant material. Two matched. One showed a significant difference the authors said could indicate adulteration. Four more were described as questionable.

And there is nothing to standardize against. No constituent has ever been identified as the active one, so no marker compound exists to standardize a product to. The ratios printed on bottles — 10:1, 20:1 — describe a mass reduction from unspecified material by an unspecified solvent, with nothing assayed at the end.

The plant part does not match either. Every rodent study, for both the testosterone finding and the toxicity findings, used the stem. The traded commercial ingredient, as described in a European regulatory filing, is a mixed extract of root, stem and aerial parts. The plant's own chemistry differs by part — saponins concentrate in the root, phenolics and flavonoids in the stem and leaf. So the material in a capsule is not the material in the study, in either direction.

One regulatory fact nobody mentions. In June 2025 the European Commission, on a request from the Czech Republic, classified Vangueria agrestis — the current botanical name for Fadogia agrestis — as a novel food, on the grounds that there is insufficient evidence of significant consumption as a food in the EU before May 1997. In practice that means it cannot lawfully be sold as a food supplement in the EU without a full safety dossier and authorization, and no such authorization exists.

Food first

Getting Fadogia Agrestis from food

There is no food route, and in this case that is the useful answer rather than a dodge.

Fadogia agrestis is a shrub of the West African savannah. It has a traditional use in parts of Nigeria, taken as a stem decoction, and the one dose in the whole literature that did not produce permanent damage in rats — 18 mg/kg — is there because it is the dose used in that folk practice. Nobody eats this plant as food anywhere, which is precisely the basis on which the European Commission classified it as a novel food in 2025.

So the honest framing is that a traditional-use dose was taken out of its context, concentrated into an extract of unknown ratio, scaled up by roughly three to seven times, and sold to be taken daily for months. The traditional practice is not a safety precedent for that.

What the food-first answer actually is, for the thing people buy this to address. The dietary and lifestyle inputs with real evidence behind them for testosterone in men are unglamorous and well established: enough sleep, enough total calories, enough dietary fat, adequate zinc and vitamin D if you are short of either, resistance training, and not carrying excess body fat. None of them will make a headline, all of them are measurable, and every one has more human evidence behind it than this plant has of any kind.

If low testosterone is a real concern, the next step is a blood test and a doctor, not a capsule whose contents five independent analyses could not confirm.

What the guide adds

The part that is not on this page

Everything above is the assessment. What the guide adds for Fadogia Agrestis is the protocol:

• Optimal Form
• Bioavailability
• Purity Red Flags
• Stack With / Avoid

147 entries across nine categories, every one graded against the clinical literature the same way.

Get The Complete Supplement Guide →

About the author

Who graded this

Daniel Edlund is a Le Cordon Bleu-trained private chef in Los Angeles, a certified personal trainer and strength coach, and an internationally licensed massage therapist. Thirty years of strength training and fifteen years cooking in private estate kitchens. He is the author of The Complete Supplement Guide, which grades 147 entries against the clinical literature, and of The EASY Way to Organic Cooking, first published in 2013.

More about Daniel →

This page is information, not medical advice. Supplements interact with prescription medication and with each other, and the right answer depends on your own bloodwork and history. Talk to your doctor before starting anything, particularly if you are pregnant, nursing, managing a health condition, or already taking medication.

Also in Hormonal Support & Vitality

Related entries

• Chrysin — Overhyped
• Stinging Nettle Root — Emerging evidence
• Wild Yam / Diosgenin — Overhyped
• Calcium D-Glucarate — Emerging evidence
• Pine Pollen — Overhyped
• Pregnenolone — Emerging evidence
• Tribulus Terrestris — Overhyped
• CLA — Overhyped
• Forskolin — Overhyped
• Raspberry Ketones — Overhyped

All 147 entries, graded →